Novartis
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.About NVS
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.
NVS Key Statistics
Stock Snapshot
With a market cap of 276.1B, Novartis(NVS) trades at $129.87. The stock has a price-to-earnings ratio of 17.66 and currently yields dividends of 2.5%.
During the trading session on 2025-11-28, Novartis(NVS) shares reached a daily high of $129.92 and a low of $129.79. At a current price of $129.87, the stock is +0.1% higher than the low and still -0.0% under the high.
Trading activity shows a volume of 4.17K, compared to an average daily volume of 1.85M.
Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.
Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.
NVS News
Key Points It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma. 10 stocks we...
On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and olde...
TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...
Analyst ratings
53%
of 30 ratingsMore NVS News
BofA upgraded Novartis (NVS) to Buy from Neutral with a price target of CHF 117, up from CHF 111. A long-standing overhang for investors has been the company’s...
In a report released today, Sachin Jain from Bank of America Securities upgraded Novartis AG to a Buy, with a price target of CHF117.00. TipRanks Black Friday S...
Novartis (NVS) “announced that the US Food and Drug Administration has approved Itvisma, onasemnogene abeparvovec-brve, for the treatment of children two years...
Labcorp (LH) announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis’ executive leadership team, to its Board of D...